| 陈 珂,钱 会,张孝飞,王寸寸,蒋亚林.地奈德福莫特罗联合异丙托溴胺治疗慢性阻塞性肺疾病急性加重期的疗效及对FeNO、cTnI的影响[J].,2022,(4):781-785 |
| 地奈德福莫特罗联合异丙托溴胺治疗慢性阻塞性肺疾病急性加重期的疗效及对FeNO、cTnI的影响 |
| Efficacy of Budesonide Formoterol Combined with Ipratropium Bromide in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Its Effect on FeNO and cTnI |
| 投稿时间：2021-05-24 修订日期：2021-06-20 |
| DOI：10.13241/j.cnki.pmb.2022.04.038 |
| 中文关键词: 布地奈德福莫特罗 异丙托溴胺 慢性阻塞性肺疾病 急性加重期 呼出气一氧化氮 心肌肌钙蛋白 |
| 英文关键词: Budesonide Formoterol Ipratropium bromide Chronic obstructive pulmonary disease Acute exacerbation Exhaled nitric oxide Cardiac troponin |
| 基金项目:安徽省自然科学基金项目（170805MH178） |
|
| 摘要点击次数: 471 |
| 全文下载次数: 246 |
| 中文摘要: |
| 摘要 目的：探讨布地奈德福莫特罗联合异丙托溴胺治疗 慢性阻塞性肺疾病急性加重期的疗效及对呼出气一氧化氮（FeNO）、心肌肌钙蛋白（cTnI）的影响 。方法：选择2020年7月-2021年5月在我院接受治疗的80例慢性阻塞性肺疾病急性加重期患者，采用随机数表法分为试验组（n=41）和对照组（n=39）。对照组给予异丙托溴胺治疗，试验组在对照组的基础上联合布地奈德福莫特罗治疗。比较两组临床疗效、FeNO、cTnI、白细胞介素6（IL-6）、超敏C反应蛋白（CRP）、临床症状改善情况及不良反应发生情况。结果：治疗后，两组总有效率比较差异显著（P<0.05）；治疗前，试验组和对照组FeNO、cTnI比较无显著差异；治疗后，试验组和对照组FeNO、cTnI均随着时间的推移而降低，且试验组均低于对照组，差异显著（P<0.05）；治疗前，试验组和对照组血清IL-6及CRP比较无显著差异；治疗后，试验组和对照组血清IL-6及CRP均随着时间的推移而降低，且试验组均低于对照组，差异显著（P<0.05）；试验组憋喘、咳嗽、哮鸣音及湿啰音消失需要的时间均显著低于对照组，差异显著（P<0.05）；两组不良反应总发生率为9.76%、17.95%，无显著差异（P>0.05）。结论：在慢性阻塞性肺疾病急性加重期中应用布地奈德福莫特罗联合异丙托溴胺治疗疗效显著，可有效改善患者FeNO、cTnI水平，且不会增加并发症。 |
| 英文摘要: |
| ABSTRACT Objective: To study Efficacy of budesonide formoterol combined with ipratropium bromide in the treatment of acute exacerbation of chronic obstructive pulmonary disease and its effect on Expiratory nitric oxide (FeNO), cardiac troponin (cTnI). Methods: 80 patients with acute exacerbation of CHRONIC obstructive pulmonary disease treated in our hospital from July 2020 to May 2021 were selected and divided into experimental group (n=41) and control group (n=39) by random number table method. The control group was given ipratropium bromide treatment, the experimental group was combined with budesonide formoterol treatment on the basis of the control group. Clinical efficacy, FeNO, cTnI, INTERleukin-6 (IL-6), hypersensitive C-reactive protein (CRP), improvement of clinical symptoms and occurrence of adverse reactions were compared between the two groups. Results: After treatment, the total effective rate of the two groups was significantly different (P<0.05); Before treatment, there was no significant difference in FeNO and cTnI between the experimental group and the control group. After treatment, FeNO and cTnI in experimental group and control group decreased over time, and experimental group was lower than control group, the difference was significant (P<0.05); Before treatment, there were no significant differences in serum IL-6 and CRP between experimental group and control group. After treatment, serum IL-6 and CRP in experimental group and control group decreased over time, and the experimental group was lower than the control group, the difference was significant (P<0.05); The time required for the disappearance of dyspnea, cough, wheezing and wet rales in experimental group was significantly lower than that in control group (P<0.05); The total incidence of adverse reactions between the two groups was 9.76% and 17.95%, with no significant difference (P>0.05). Conclusion: In the acute exacerbation of chronic obstructive pulmonary disease, budesonide formoterol combined with ipratropium bromide has a significant therapeutic effect, which can effectively improve the levels of FeNO and cTnI in patients without increasing complications. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
